Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue
An in Vivo Proof of Principle Trial to Determine Whether the Nutritional Supplement Conjugated Linoleic Acid (CLA, Clarinol™) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue
Sponsor: Dartmouth College
A EARLY_PHASE1 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Dartmouth College and has accumulated 9 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Dec 2022 [monthly]
Completed EARLY_PHASE1
▶ Show 4 earlier versions
-
May 2019 — Jan 2021 [monthly]
Completed EARLY_PHASE1
Status: Unknown Status → Completed
-
Jun 2018 — May 2019 [monthly]
Unknown Status EARLY_PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status Phase 0
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dartmouth College
- Dartmouth-Hitchcock Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .